[1] |
HUPPERT L A, GUMUSAY O, IDOSSA D, et al. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer[J]. CA Cancer J Clin, 2023, 73(5): 480-515.
doi: 10.3322/caac.v73.5
|
[2] |
WU Y M, ZHANG Y, PI H, et al. Current therapeutic progress of CDK4/6 inhibitors in breast cancer[J]. Cancer Manag Res, 2020, 12: 3477-3487.
doi: 10.2147/CMAR.S250632
pmid: 32523378
|
[3] |
中华人民共和国国家卫生健康委员会. 乳腺癌诊疗指南(2022年版)[J]. 中国合理用药探索, 2022, 19(10): 51.
|
|
National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of breast cancer (2022 edition)[J]. China Licens Pharm, 2022, 19(10): 51.
|
[4] |
GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
doi: 10.6004/jnccn.2022.0030
|
[5] |
ONESTI C E, JERUSALEM G. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis[J]. Expert Rev Anticancer Ther, 2021, 21(3): 283-298.
doi: 10.1080/14737140.2021.1852934
|
[6] |
GRINSHPUN A, TOLANEY S M, BURSTEIN H J, et al. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer[J]. NPJ Breast Cancer, 2023, 9(1): 15.
doi: 10.1038/s41523-023-00520-7
pmid: 36949066
|
[7] |
GAO J J, CHENG J, BLOOMQUIST E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis[J]. Lancet Oncol, 2020, 21(2): 250-260.
doi: S1470-2045(19)30804-6
pmid: 31859246
|
[8] |
SCHETTINI F, GIUDICI F, GIULIANO M, et al. Overall survival of CDK4/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis[J]. J Natl Cancer Inst, 2020, 112(11): 1089-1097.
doi: 10.1093/jnci/djaa071
pmid: 32407488
|
[9] |
THILL M, SCHMIDT M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer[J]. Ther Adv Med Oncol, 2018, 10: 1758835918793326.
|
[10] |
国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会肿瘤药物临床研究专业委员会, 徐兵河, 等. CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识[J]. 中华肿瘤杂志, 2021, 43(4): 405-413.
|
|
Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Drug Clinical Research Professional Committee of China Anti-Cancer Association, XU B H, et al. Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer[J]. Chin J Oncol, 2021, 43(4): 405-413.
|
[11] |
DESNOYERS A, NADLER M B, KUMAR V, et al. Comparison of treatment-related adverse events of different cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis[J]. Cancer Treat Rev, 2020, 90: 102086.
doi: 10.1016/j.ctrv.2020.102086
|
[12] |
RASCHI E, FUSAROLI M, ARDIZZONI A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment[J]. Breast Cancer Res Treat, 2021, 186(1): 219-227.
doi: 10.1007/s10549-020-06001-w
|
[13] |
RASCHI E, FUSAROLI M, LA PLACA M, et al. Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system[J]. Am J Clin Dermatol, 2022, 23(2): 247-255.
doi: 10.1007/s40257-021-00645-0
|
[14] |
SAKAEDA T, TAMON A, KADOYAMA K, et al. Data mining of the public version of the FDA Adverse Event Reporting System[J]. Int J Med Sci, 2013, 10(7): 796-803.
doi: 10.7150/ijms.6048
pmid: 23794943
|
[15] |
Administration USDO. FDA Adverse Event Reporting System (FAERS) quarterly data extract files[EB/OL] (2023-04-27)[2023-7-14]. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
|
[16] |
CANDORE G, JUHLIN K, MANLIK K, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases[J]. Drug Saf, 2015, 38(6): 577-587.
doi: 10.1007/s40264-015-0289-5
|
[17] |
尚鹏辉, 詹思延. 数据挖掘在药品不良反应信号检出和分析中的应用(下): 药物流行病学研究新方法系列讲座(三)[J]. 中国药物应用与监测, 2009, 6(3): 187-190.
|
|
HANG P H, ZHAN S Y. Application of data excavation in the signal detection and analysis of adverse drug reactions(third)[J]. Chin J Drug Appl Monit, 2009, 6(3): 187-190.
|
[18] |
Agency EM. Designated Medical Event (DME) list[EB/OL] (2020-06-15)[2023-7-14]. https://www.ema.europa.eu/documents/other/designated-medical-event-dme-list_en.xls.
|
[19] |
BRAAL C L, JONGBLOED E M, WILTING S M, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331.
doi: 10.1007/s40265-020-01461-2
pmid: 33369721
|
[20] |
WANDER S A, O'BRIEN N, LITCHFIELD L M, et al. Targeting CDK4 and 6 in cancer therapy: emerging preclinical insights related to abemaciclib[J]. Oncologist, 2022, 27(10): 811-821.
doi: 10.1093/oncolo/oyac138
pmid: 35917168
|
[21] |
LI J, FU F M, YU L W, et al. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials[J]. Breast Cancer Res Treat, 2020, 180(1): 21-32.
doi: 10.1007/s10549-020-05528-2
|
[22] |
THIBAULT S, HU W Y, HIRAKAWA B, et al. Intestinal toxicity in rats following administration of CDK4/6 inhibitors is independent of primary pharmacology[J]. Mol Cancer Ther, 2019, 18(2): 257-266.
doi: 10.1158/1535-7163.MCT-18-0734
pmid: 30401694
|
[23] |
CHAPPELL J C, TURNER P K, PAK Y A, et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate[J]. Clin Pharmacol Ther, 2019, 105(5): 1187-1195.
doi: 10.1002/cpt.1296
pmid: 30449032
|
[24] |
VRANA E, MYLONA S, BOBOS M, et al. Ribociclib and palbociclib-induced erythema multiforme: a case report[J]. Oxf Med Case Reports, 2022, 2022(11): omac116.
doi: 10.1093/omcr/omac116
|
[25] |
ZHANG P, ZHANG Q Y, TONG Z S, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2023, 24(6): 646-657.
doi: 10.1016/S1470-2045(23)00172-9
|
[26] |
XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021, 27(11): 1904-1909.
doi: 10.1038/s41591-021-01562-9
pmid: 34737452
|